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Abstract
Background: Grading of patients with aneurysmal subarachnoid hemorrhage (aSAH) is often confounded by seizure,
hydrocephalus or sedation and the prediction of prognosis remains difficult. Recently, copeptin has been identified as a
serum marker for outcomes in acute ischemic stroke and intracerebral hemorrhage (ICH). We investigated whether copeptin
might serve as a marker for severity and prognosis in aSAH.
Methods: Eighteen consecutive patients with aSAH had plasma copeptin levels measured with a validated
chemiluminescence sandwich immunoassay. The primary endpoint was the association of copeptin levels at admission
with the World Federation of Neurological Surgeons (WFNS) grade score after resuscitation. Levels of copeptin were
compared across clinical and radiological scores as well as between patients with ICH, intraventricular hemorrhage,
hydrocephalus, vasospasm and ischemia.
Results: Copeptin levels were significantly associated with the severity of aSAH measured by WFNS grade (P = 0.006), the
amount of subarachnoid blood (P = 0.03) and the occurrence of ICH (P = 0.02). There was also a trend between copeptin
levels and functional clinical outcome at 6-months (P = 0.054). No other clinical outcomes showed any statistically significant
association.
Conclusions: Copeptin may indicate clinical severity of the initial bleeding and may therefore help in guiding treatment
decisions in the setting of aSAH. These initial results show that copeptin might also have prognostic value for clinical
outcome in aSAH.
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Introduction
For assessment of the severity of aneurysmal subarachnoid
hemorrhage (aSAH), the World Federation of Neurological
Surgeons (WFNS) grade is the current gold standard [1]. The
condition of patients with aSAH may however be confounded by
seizure, hydrocephalus or sedation [2]. Treatment decisions such
as occlusion of an aneurysm are based on clinical grading [1].
Prediction of outcome remains difficult and complicates decision-
making for active treatment [3]. Copeptin has evolved as a serum
marker for the severity of disease and outcome of patients in
spontaneous intracerebral hemorrhage (ICH), ischemic stroke and
sepsis [4,5,6]. It is released in an equimolar ratio with vasopressin
from a common precursor protein, pre-provasopressin [7].
Vasopressin is a hypothalamic hormone that is stimulated by
different stressors. Vasopressin potentiates the action of cortico-
trophin releasing hormone and leads downstream to a release of
adrenocorticotropic hormone (ACTH) and production of cortisol
[8]. Copeptin is a 39 amino-acid glycopeptide and is equivalent to
the C-terminal part of pre-provasopressin [7]. Because copeptin is
stable for days, it can be easily measured in blood samples [7].
Copeptin therefore is a surrogate marker for vasopressin release
and might act as a marker for stress response [7]. The aim of this
prospective study was to elucidate whether copeptin could be used
as a marker for severity and prognosis of aSAH.
Materials and Methods
Patients with aSAH admitted to our neurosurgical unit from 21
December 2010 through 21 March 2011 were prospectively
included. The study was approved by the Bern Canton Ethics
Committee (Bern, Switzerland) and written informed consent was
obtained from all patients (Clinical Trial Registration Information
NCT00878813).
We collected demographic, clinical, radiological and outcome
data for all patients. Venous blood was collected in ethylenedi-
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aminetetraacetic acid (EDTA) tubes on admission and a sample
was analyzed for copeptin.
Samples were placed on ice, centrifuged at 3000 g, and plasma
aliquoted and frozen at 270uC. We analyzed copeptin levels using
a validated commercial chemiluminescence sandwich immunoas-
say (Thermo Scientific B.R.A.H.M.S LIA CT-proAVP,
B.R.A.H.M.S GmbH, Henningsdorf, Germany) [5].
For grading, the best Glasgow Coma Scale (GCS) after
resuscitation in unsedated patients was used [1,9]. Imaging at
admission was used to determine Fisher grade, volume of ICH and
hydrocephalus [10,11]. Patients were divided into 2 groups: those
with diffuse subarachnoid blood (Fisher grade 2 and 4), and
patients with thick subarachnoid blood clot (Fisher grade 3).
Admission CT angiography or digital subtraction angiography was
used for aneurysm detection. Aneurysm location was divided into
those originating from the anterior and posterior circulation [12].
Cerebral vasospasm and ischemic lesions were defined using the
CONSCIOUS criteria [9]. Ischemic lesions were stratified into
small (,10 mL), medium (10–100 mL) and large (.100 mL).
Clinical outcome was evaluated at the 6-month follow-up visit and
categorized according to the patient’s modified Rankin scale
(mRS) score: a good outcome was defined as mRS 0–3 and a poor
outcome as mRS 4–6.
The primary endpoint was the association of admission
copeptin levels with WFNS grade. Fisher grade, ICH, intraven-
tricular hemorrhage (IVH), hydrocephalus, vasospasm, ischemia
and mortality were defined as secondary endpoints.
Comparisons of copeptin levels with clinical scales and end-
points were calculated using an unpaired Mann-Whitney-U test
(StataCorp, College Station, TX, USA). Two-sided P-values,0.05
were considered significant.
Results
Our study included a total of 18 patients (12 women and 6
men), and the median age was 57 years (interquartile range (IQR)
48–67 years). Copeptin values and distributions are shown in
Table 1 and Fig. 1. The overall median copeptin level at admission
was 17.0 pmol/L (IQR 3.3–38.4). The median copeptin level was
6.8 pmol/L for patients WFNS 1 (n= 8), 2.8 pmol/L for WFNS 2
(n = 2), 7.1 pmol/L for WFNS 3 (n = 1), 17.4 pmol/L for WFNS 4
(n = 5) and 79.9 pmol/L for WFNS 5 (n = 2). Median intrapa-
renchymal hematoma volume was 27.5 mL. Three patients
developed ischemic lesions, all of which were assessed as small
(,10 mL).
Higher copeptin levels were significantly associated with poor-
grade (WFNS 4–5) aSAH, Fisher grade 3 and ICH (Table 1). 15
out of 18 patients had a proven aneurysm. Among the remaining 3
patients, one had a perimesencephal SAH, one died before an
aneurysm could be detected, and in one patient – although having
a SAH Fisher grade 3 – the aneurysm could not be proven. 11
aneurysms were located in the anterior and 4 in the posterior
circulation. Aneurysm location was not significantly associated
with copeptin levels (P = 0.38; Table 1). In addition, sex was not
significantly associated with copeptin levels; the 6 male patients
had a median copeptin level of 21.4 pmol/L compared to
7 pmol/L for the 12 female patients (Table 1). Copeptin levels
in patients with a good outcome were lower than those with a poor
outcome (P= 0.054, Table 1). Patients that died after aSAH had
median copeptin levels three times higher than aSAH survivors at
6-months (P = 0.277).
Discussion
The main finding of the current study is that copeptin reflects
the severity of aSAH, as assessed by the WFNS score after
resuscitation and similarly to the grading of the severity of
ischemic stroke [4]. The median copeptin level of our study cohort
was comparable to reported median levels in cohorts with
hemorrhagic stroke (16.3 pmol/L) and ischemic stroke
(11.6 pmol/L) [4,6]. Median copeptin levels in healthy individuals
have been reported, and range from 3.7 to 4.2 pmol/L [4,7,13].
In the current study, the presence of ICH in patients with aSAH
was statistically significantly associated with higher levels of
copeptin. Zweifel et al. showed that higher levels of copeptin in
patients with ICH were associated with increased hematoma
volume and poorer clinical outcome [6]. We have now demon-
strated a similar relationship in aSAH patients; increased copeptin
is significantly associated with the amount of subarachnoid blood.
Due to the fact that the majority of poor grade SAH patients also
display an ICH, the data must be interpreted with caution.
Whether high levels of copeptin can be attributed solely to the
severity of the SAH as rated by the WFNS grade or also to the
occurrence of ICH cannot be answered. Yet in general, the
occurrence of ICH has an impact on the severity of the clinical
picture and outcome of SAH patients. We found no statistically
significant association of copeptin with IVH, hydrocephalus,
vasospasm, aneurysm location, sex, delayed ischemia, or mortality
within 6 months, although there was a trend towards an
association with functional outcome.
Delayed cerebral vasospasm is a well-recognized contributor to
poor outcome [2,9]. The cascade of neurovascular events
encompassing changes early after the ictus as well as delayed
cerebral ischemia due to vasospasm determines final outcome. So
far, biomarkers on admission fail to reliably predict delayed
Figure 1. Copeptin Level by WFNS Grade. The figure represents a
boxplot of copeptin values per WFNS grade. Displayed are lowest,
highest and median copeptin values (pmol/L), with upper (75%) and
lower (25%) quartiles.
doi:10.1371/journal.pone.0053191.g001
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cerebrovascular events [14]. In our opinion admission copeptin
levels might not predict later cerebrovascular events, yet serial
testing throughout the course of the disease might show an
association. Still, in a recent retrospective analysis, Zhu et al. found
a significant association between copeptin and vasospasm [15].
However, in line with our current results, they concluded that
admission copeptin levels should not be used as a predictor for
vasospasm because clinical grades had a higher accuracy [15].
Whether copeptin release is SAH specific or reflects a general
stress response remains unclear. Copeptin is released from the
hypothalamus in an equimolar ratio with vasopressin. The
increase of copeptin in SAH patients might therefore rather result
from activation of the hypothalamo-pituitary-adrenal axis as a
response to stress [4]. This is very likely since, besides ischemic and
hemorrhagic stroke, this has been shown for various diseases like
respiratory tract infection, heart failure and shock [5,16,17]. Still,
this does not exclude the role of copeptin as a potential biomarker
for severity of SAH.
Despite the strength of the prospective protocol and the detailed
patient characterization, our pilot study was too small to draw
definitive conclusions. However the results of this study, as well as
the similar findings by Zhu et al. [15], should encourage further
investigation on copeptin in patients with aSAH.
Conclusions
Copeptin levels on admission were statistically significantly
associated with severity of aSAH according to the WFNS grade,
the amount of subarachnoid blood and ICH. Copeptin levels
tended to be higher in patients with unfavorable clinical outcome.
Table 1. Copeptin levels and characteristics of study patients.
n Median copeptin level (IQR) (pmol/L) p-value
WFNS gradea
Good-grade 11 6.8 (6.6–17.4)
Poor-grade 7 26.3 (18.3–204) P=0.006
Fisher grade
Diffuse blood (Fisher grade 2 and 4) 3 1.6 (1.5–3.3)
Thick clot (Fisher grade 3) 15 18.3 (6.8–60.4) P=0.027
ICH
Yes 6 52.5 (17.4–204)
No 12 6.7 (2.2–22.3) P=0.02
IVH
Yes 11 17.4 (6.6–38.4)
No 7 7.1 (1.6–79.9) P = 0.89
Hydrocephalus
Yes 12 17.9 (5–32.4)
No 6 6.7 (3.3–60.4) P = 0.682
Vasospasm
Yes 5 26.3 (24.5–60.4)
No 13 7.1 (2.8–18.3) P = 0.15
Ischemia
Yes 3 24.5 (1.3–60.4)
No 15 16.5 (3.3–38.4) P = 1.0
Sex
Male 6 21.4 (12.7–94.3)
Female 12 7 (2.9–51.9) P = 0.5
Aneurysm location
Anterior circulation 11 17.4 (6.8–60.4)
Posterior circulation 4 2.2 (1.4–29.5) P = 0.38
Outcomeb
Good 13 6.8 (2.8–24.5)
Poor 5 26.3 (17.4–204) P = 0.054
Mortality
Survivors 14 7.0 (2.8–38.4)
Deceased 4 21.9 (17–115.2) P = 0.277
IQR: interquartile range; WFNS: World Federation of Neurological Surgeons; ICH: intracerebral hemorrhage; IVH: intraventricular hemorrhage.
aWFNS grade: Good-grade WFNS 1–3; Poor-grade: WFNS 4–5.
bmodified Rankin Scale (mRS) score 0–3: Good outcome; mRS 4–6: Poor outcome.
doi:10.1371/journal.pone.0053191.t001
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Copeptin might therefore evolve as a useful marker for prognosis
in subarachnoid hemorrhage.
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